Form S-3 Karyopharm Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Karyopharm Therapeutics (KPTI) files for 8.84M share offering by selling stockholders
May 4, 2026 4:41 PM EDTKaryopharm Therapeutics (NASDAQ: KPTI) has filed for up to 8,843,036 share offering by selling stockholders.
... MoreKaryopharm Therapeutics (KPTI) files $400M mixed shelf
May 4, 2026 4:38 PM EDTKaryopharm Therapeutics (NASDAQ: KPTI) has filed $400,000,000 mixed shelf of:
Debt Securities
Common Stock
Preferred Stock
Units
Warrants
... More